Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04947956

Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma Clinical Trial

Official title:
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma in China: a Real-world Study

Clinical Trial Summary

Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority of HCC cases present at an advanced stage, and are thus not amenable to surgery. Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens, have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells， which has been approved for the second-line treatment of advanced HCC. This observational study aims to evaluate the safety and efficacy of camrelizumab in Chinese unresectable HCC in the real world.

Clinical Trial Description

Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority of HCC cases present at an advanced stage, and are thus not amenable to surgery. Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens, have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells，which has been approved for the second-line treatment of advanced HCC. This multi-center, open-label, observational study aims to evaluate the safety and efficacy of camrelizumab in Chinese unresectable HCC in the real world. This study also aims to evaluate the treatment of camrelizumab in subgroups, to provide information of treatment regimens and efficacy in clinical practice. The anticipated sample size is 1000, and the camrelizumab-based treatment will be determined by the investigator. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04947956
Study type Observational
Source Shanghai Zhongshan Hospital
Contact Jian Zhou, Doctor
Phone 13801914007
Email zhou.jian@zs-hospital.sh.cn
Status Not yet recruiting
Phase
Start date September 1, 2021
Completion date September 1, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Completed NCT00988741 - Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy Phase 2
Recruiting NCT03942328 - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Phase 1/Phase 2
Completed NCT01900002 - Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 2
Completed NCT06315101 - Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
Completed NCT01004978 - Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 3
Active, not recruiting NCT01217034 - Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib Phase 2
Terminated NCT03695250 - BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Phase 1/Phase 2
Completed NCT02006030 - Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma Phase 2
Active, not recruiting NCT03896646 - Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) N/A
Recruiting NCT05135364 - HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure Phase 2
Recruiting NCT06117891 - An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
Recruiting NCT05957640 - Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma Phase 1
Recruiting NCT04736121 - Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients N/A
Recruiting NCT05168163 - Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Phase 2
Withdrawn NCT03345225 - A Clinical Study of Precision TACE (P-TACE) With Surefire N/A
Recruiting NCT05667064 - Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT02989870 - Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma Phase 1
Active, not recruiting NCT04829383 - A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma Phase 2